5 completed, 1 unknown. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Alpha Blockade for Pheochromocytoma Phenoxybenzamine, Doxazosin - Pheochromocytoma, Paraganglioma | Phase 3 | Completed | University of California, Los Angeles | 39 | 2017-05-05 | 2023-11-20 |
| Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma 123I-mIBG (meta-iodobenzylguanidine) - Pheochromocytoma, Neuroblastoma | Phase 3 | Completed | GE Healthcare | 251 | 2005-08-02 | 2019-05-31 |
| Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Indium-111 pentetreotide - Neuroendocrine Tumors | Phase 2 / Phase 3 | Completed | Radio Isotope Therapy of America | 200 | 2005-08-01 | 2023-04-03 |
| Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1996-04-01 | 2012-07-11 |
| Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 350 | 1995-02-01 | 2014-08-08 |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors 123I-meta-iodobenzylguanidine - Pheochromocytoma, Neuroblastoma | Phase 3 | Unknown | Vancouver Coastal Health | 2011-06-15 |
Pheochromocytoma (6) · Carcinoid Tumor (2) · Endometrial Neoplasms (2) · Fibrosarcoma (2) · Hemangiopericytoma, Malignant (2) · Hemangiosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Kidney Neoplasms (2) · Leiomyosarcoma (2) · Liposarcoma (2) · Malignant mesenchymal tumor (2) · Neuroblastoma (2) · Neurofibrosarcoma (2) · Ovarian Neoplasms (2)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (5) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Adnexal Diseases (2) · Carcinoma (2) · Carcinoma, Neuroendocrine (2)
Doxorubicin (2) · Filgrastim (2) · Ifosfamide (2) · 3-Iodobenzylguanidine (1) · Chemotherapy, Adjuvant (1) · Doxazosin (1) · Phenoxybenzamine (1) · Radiotherapy (1)
European Organisation for Research and Treatment of Cancer - EORTC (2) · GE Healthcare (1) · Radio Isotope Therapy of America (1) · University of California, Los Angeles (1) · Vancouver Coastal Health (1)
United States (3) · Canada (2) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Portugal (1) · Slovakia (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
A.N. Van Geel, MD (1) · Daniel Worsley, MD (1) · Diane McCaul (1) · Ebrahim Delpassand, M.D. (1) · Laurence H. Baker, DO, FACOI (1) · Michael Yeh, MD (1) · Penella J. Woll, MD, PhD (1) · Ronald H. Blum, MD (1) · Thor A. Alvegard, MD, PhD (1) · Vivien H.C. Bramwell, MB, BS, PhD, FRCP (1)
PMID 12192533, PMID 20546874, PMID 22954508, PMID 24939623, PMID 25456922, PMID 27561909